Morgan Stanley Raises Vir Biotechnology Target Price to $15
Wednesday, 5 June 2024, 16:14
Morgan Stanley Boosts Vir Biotechnology Target Price
The latest report from Morgan Stanley has raised Vir Biotechnology's target price to $15 from $12. This upgrade signifies a positive outlook on the company's performance and market potential.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.